Edwards Lifesciences Corp (NYSE: EW) open the trading on Wednesday, with a bit cautious approach as it glided -0.59% to $72.93, before settling in for the price of $73.36 at the close. Taking a more long-term approach, EW posted a 52-week range of $64.89-$83.00.
The Healthcare sector firm’s twelve-monthly sales growth has been -2.36% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -2.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 3.25%. This publicly-traded company’s shares outstanding now amounts to $587.90 million, simultaneously with a float of $575.05 million. The organization now has a market capitalization sitting at $42.82 billion.
Edwards Lifesciences Corp (EW) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. Edwards Lifesciences Corp’s current insider ownership accounts for 2.05%, in contrast to 86.65% institutional ownership. According to the most recent insider trade that took place on Aug 25 ’25, this organization’s CVP, TMTT sold 2,500 shares at the rate of 81.95, making the entire transaction reach 204,865 in total value, affecting insider ownership by 30,996.
Edwards Lifesciences Corp (EW) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.61 per share during the current fiscal year.
Edwards Lifesciences Corp’s EPS increase for this current 12-month fiscal period is 3.25% and is forecasted to reach 2.80 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.05% through the next 5 years, which can be compared against the -2.36% growth it accomplished over the previous five years trading on the market.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Let’s observe the current performance indicators for Edwards Lifesciences Corp (EW). It’s Quick Ratio in the last reported quarter now stands at 3.87. Alongside those numbers, its PE Ratio stands at $49.79, and its Beta score is 1.03. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.53. Similarly, its price to free cash flow for trailing twelve months is now 72.83.
In the same vein, EW’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.46, a figure that is expected to reach 0.59 in the next quarter, and analysts are predicting that it will be 2.80 at the market close of one year from today.
